Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
about
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaBest Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on AsparaginaseDevelopment of asparaginase Erwinia chrysanthemi for the treatment of acute lymphoblastic leukemiaHow to manage asparaginase hypersensitivity in acute lymphoblastic leukemiaSuccessful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginaseEffect of premedications in a murine model of asparaginase hypersensitivityTreatment of children with advanced-stage lymphoblastic lymphoma with pegaspargaseDexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.Pharmacogenomics in pediatric leukemia.Asparaginase-associated toxicity in children with acute lymphoblastic leukemia.Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamicsErwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.High-throughput asparaginase activity assay in serum of children with leukemiaA 50-year journey to cure childhood acute lymphoblastic leukemiaPEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma.Clinical developments in nanotechnology for cancer therapy.Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices.Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel.Erwinia asparaginase in pediatric acute lymphoblastic leukemia.Managing hypersensitivity to asparaginase in pediatrics, adolescents, and young adults.Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia.Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors.Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.A retrospective comparison of Escherichia coli and polyethylene glycol-conjugated asparaginase for the treatment of adolescents and adults with newly diagnosed acute lymphoblastic leukemia.Clinical application of asparaginase activity levels following treatment with pegaspargase.Comparison of Native Escherichia Coli L-Asparaginase Versus Pegylated Asparaginase, in Combination with Ifosfamide, Methotrexate, Etoposide, and Prednisolone (IMEP), in Extranodal NK/T Cell Lymphoma, Nasal Type (NTCL).Personalized nanomedicine: a rapid, sensitive, and selective UV-vis spectrophotometry method for the quantification of nanostructured PEG-asparaginase activity in children's plasma
P2860
Q26738640-F1B04E2A-5877-4CD0-AED2-1EAAC2C8FC30Q26784116-30FCD87E-92DF-4A07-8FA5-5B5C19FEA3A5Q26825970-3BAC6B59-E385-425F-8835-DCEAB997C987Q27026952-49B8E541-CA64-4404-AB52-23574DC0488BQ34064049-C0318EC3-E31E-4ADB-80B6-A60EAA7BA7C7Q35156439-B7F5B089-2AE6-4BAD-A8DA-BC5009EB1043Q35177328-E6720433-ED1D-4CBB-9849-34DD240DB705Q35776973-8B7D90D0-F887-4490-B031-05EB74DCE3BAQ36727952-B15B7BDD-967E-4DB4-9E99-E3BA60A0A6E2Q36762608-76368A7B-CCDF-4962-9CF4-F0910C3C9A63Q36966669-CFDEAB1A-5266-4E81-BF75-E7949C5B077DQ37046992-B75792EB-B751-4467-A40A-FBB1FD333D2DQ37063860-13E9EEFD-615D-47E4-8760-66389B82A568Q37166753-3E1902E5-C12A-43BD-B2FE-488047B547ACQ37697320-F996FF02-A848-4C12-A736-B6B1CE840310Q37765187-538C9858-5089-415D-BE86-28F7BE061583Q37902619-1B55DCA2-AEA2-4A7A-B2E7-16CAC014C190Q37914185-5E767844-7D52-4606-A4DE-20DCD02F20B4Q38040418-F2E198AA-ED21-42AD-883E-2D5BD7BAE059Q38079075-FD599CB8-2220-45DD-8CEC-5867C83E27EFQ38248280-7FDBCCEE-0611-46A7-9B8C-0E85191250EAQ39026261-7DCD4691-E11F-4C7B-B91B-76CC0BDE87E1Q44501918-9384D49E-5AB9-4909-A1AE-BA6D74DC417BQ45994014-C1197C29-A4E4-429B-9917-7889E19957BDQ47369397-B9C025C0-2E4E-4712-834D-92627F3B1CE4Q48203946-128CFEEB-4897-4508-A2DD-41AB800AC6ECQ49412789-69F1C6D5-2D8F-4647-BDD5-F018D5F40C52Q51013006-AC2F3D6D-BDA8-4330-8EC1-EB69EF05095BQ54222267-D38DF23B-2AC6-4D45-8E7C-A69419EDE5C2Q58563335-7EA7591F-DB9A-4A4E-A181-04D65F3AEA63
P2860
Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Comparison of native E. coli a ...... acute lymphoblastic leukemia.
@ast
Comparison of native E. coli a ...... acute lymphoblastic leukemia.
@en
type
label
Comparison of native E. coli a ...... acute lymphoblastic leukemia.
@ast
Comparison of native E. coli a ...... acute lymphoblastic leukemia.
@en
prefLabel
Comparison of native E. coli a ...... acute lymphoblastic leukemia.
@ast
Comparison of native E. coli a ...... acute lymphoblastic leukemia.
@en
P2093
P2860
P356
P1476
Comparison of native E. coli a ...... acute lymphoblastic leukemia.
@en
P2093
J C Panetta
M V Relling
P2860
P304
P356
10.1038/CLPT.2009.162
P407
P577
2009-09-09T00:00:00Z